These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35969103)

  • 41. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.
    de Cuba EM; Kwakman R; Knol DL; Bonjer HJ; Meijer GA; Te Velde EA
    Cancer Treat Rev; 2013 Jun; 39(4):321-7. PubMed ID: 23244778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
    Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
    Morales-Soriano R; Esteve-Pérez N; Segura-Sampedro JJ; Cascales-Campos P; Barrios P;
    Eur J Surg Oncol; 2018 Feb; 44(2):228-236. PubMed ID: 29242018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Kok NF; Jóźwiak K; Lahaye ML; Beets GL; van Leerdam ME; Boot H; Aalbers AG
    Dis Colon Rectum; 2017 May; 60(5):477-487. PubMed ID: 28383447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
    de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
    Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases.
    Moran BJ
    Tech Coloproctol; 2017 Sep; 21(9):767-769. PubMed ID: 28936563
    [No Abstract]   [Full Text] [Related]  

  • 50. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience.
    Gupta N; Asif S; Gandhi J; Rajpurohit S; Singh S
    Indian J Gastroenterol; 2017 Mar; 36(2):126-130. PubMed ID: 28393331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review.
    van Stein RM; Aalbers AGJ; Sonke GS; van Driel WJ
    JAMA Oncol; 2021 Aug; 7(8):1231-1238. PubMed ID: 33956063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
    Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
    Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
    Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
    Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
    Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
    Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
    Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN
    J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
    Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
    Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer.
    Eng OS; Turaga KK
    J Surg Oncol; 2019 Apr; 119(5):613-615. PubMed ID: 30852849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
    BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Mehta A; Mittal R; Chandrakumaran K; Carr N; Dayal S; Mohamed F; Moran B; Cecil T
    Dis Colon Rectum; 2017 Nov; 60(11):1155-1161. PubMed ID: 28991079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.